Research Analysts Issue Forecasts for SLDB FY2025 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Solid Biosciences in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings per share of ($2.45) for the year. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share.

SLDB has been the subject of several other reports. Truist Financial assumed coverage on Solid Biosciences in a research note on Wednesday, January 8th. They set a “buy” rating and a $16.00 target price for the company. JPMorgan Chase & Co. lowered their price objective on shares of Solid Biosciences from $15.00 to $12.00 and set an “overweight” rating for the company in a research report on Tuesday, November 12th. JMP Securities assumed coverage on Solid Biosciences in a research report on Tuesday, December 10th. They issued an “outperform” rating and a $15.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Friday, January 10th. Finally, Wedbush began coverage on Solid Biosciences in a report on Friday, December 13th. They issued an “outperform” rating and a $16.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $15.30.

Solid Biosciences Stock Performance

Shares of SLDB opened at $3.26 on Wednesday. Solid Biosciences has a 52 week low of $3.03 and a 52 week high of $15.05. The stock’s 50-day moving average price is $4.56 and its 200-day moving average price is $6.49.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.12).

Insider Activity at Solid Biosciences

In other Solid Biosciences news, COO David T. Howton sold 5,072 shares of the company’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $28,403.20. Following the completion of the transaction, the chief operating officer now owns 15,663 shares in the company, valued at $87,712.80. This represents a 24.46 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alexander Cumbo sold 11,114 shares of Solid Biosciences stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $5.60, for a total value of $62,238.40. Following the sale, the chief executive officer now directly owns 38,484 shares in the company, valued at approximately $215,510.40. The trade was a 22.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 25,925 shares of company stock worth $136,853. 13.63% of the stock is owned by company insiders.

Institutional Investors Weigh In On Solid Biosciences

Several large investors have recently made changes to their positions in SLDB. The Manufacturers Life Insurance Company bought a new position in shares of Solid Biosciences in the third quarter valued at approximately $71,000. Point72 DIFC Ltd bought a new position in Solid Biosciences during the 2nd quarter valued at $58,000. MetLife Investment Management LLC boosted its stake in Solid Biosciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock valued at $95,000 after purchasing an additional 7,719 shares in the last quarter. Algert Global LLC acquired a new position in shares of Solid Biosciences during the 2nd quarter valued at $82,000. Finally, Valence8 US LP acquired a new stake in shares of Solid Biosciences in the third quarter valued at $110,000. Institutional investors and hedge funds own 81.46% of the company’s stock.

About Solid Biosciences

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.